Atlas Trials

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

Clinical trial NCT02548351 · TERMINATED

Trial details

NCT number
NCT02548351
Sponsor
Intercept Pharmaceuticals
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Non Alcoholic Steatohepatitis (NASH)
Start date
2015-09-22
Primary completion
2023-09-15
Enrollment
2477

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.